model updat ad thought
price month
 close
speak compani second opinion
sharp sell-off post-earn appear excess us
surpris see close today lose
market cap follow result guidanc
consensu even tax benefit play key role metric
incom meaning benefit ep guidanc oper
growth expect somewhat lower expect
expens assumpt somewhat higher overal still see
compani well posit driven key pharma product darzalex
xarelto imbruvica even net revenu last product
littl lighter expect given ad invest make
behind product conjunct partner maintain
outperform rate target price blue sky valuat
grey sky valuat ep estim
pleas let us know
would like updat compani model primari risk
rate target price slowdown key pharma growth
driver disappoint data on-going clinic trial
notabl model updat increas tremfya given solid uptak
date also increas zytiga estim next quarter
us still assum gener entri oct outsid us increas
zytiga meaning sinc patent expir expect
make smaller adjust product darzalex increas
estim given strong market penetr remicad lower
estim given increas price pressur due biosimilar competit
roughli in-lin guidanc expens margin
expans tax rate vs guidanc overal
total sale forecast come higher end
guidanc rang ep estim
midpoint rang
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
follow-up manag
opportun speak member team follow confer
call gain addit clariti dynam around certain product
well bake expect around fy summar
compani answer question
clariti today decis feder circuit court appeal
alreadi product
decis take away avenu potenti obtain damag inappropri
statu lawsuit alleg anticompetit practic
maintain share remicad
continu believ lawsuit merit
respond brief meaning updat near-term event
happi uptak date
essenti us psoriasi far
approv ex-u
breakdown indic key immunolog product
remicad remain rheumatolog gi
stelara sale crohn diseas rest psoriasi psoriat
growth come crohn diseas
simponi rheumatolog gi
view zytiga ip chang
disagre neg ipr announc last week impact month stay
goe octob
summari judgement case expect februari favor
need trial would vacat month stay would appeal
decis judgement favor court set date trial
expect gener competit zytiga pretti confid guidanc
rang could absorb impact gener entri
progress apalutumid
file fda grant prioriti review
pdufa data earli april
enthusiasm niraparib prostat cancer
continu see prostat cancer growth opportun see niraparib
import part
new data expect year
file
oper margin expect increas
on-going restructur program lead benefit sg cog
increas invest follow tax reform two larg item
impact number idorsia aprocitentan
legend car-t assum level go forward
reaction quarter
thought stock reaction
specul receiv question around underli oper growth
left higher
expect growth busi see risk around gener
competit price compress pharma
sustenna/ schiz sale sale salescost expensesoper incom back incom net countpf dilut forecastgrowthgrowthvarianceep charl martineau pm univers toronto
us million unless otherwis state
good amort profit expens incom back non-recur expens incom expens tax share continu analysisgross margin oper margin per changespharma devic ep charl martineau pm univers toronto
us million unless otherwis state
 expens current stockhold equityloan note rebat return tax current tax relat receiv employe stock liabil stockhold charl martineau pm univers toronto
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
 close
compani mention price
vamil divan md certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
